Overview

This trial is active, not recruiting.

Condition metastatic colorectal cancer
Treatment ezn-2208, cetuximab and irinotecan
Phase phase 2
Sponsor Enzon Pharmaceuticals, Inc.
Start date June 2009
End date October 2011
Trial size 220 participants
Trial identifier NCT00931840, EZN-2208-04

Summary

This is a Phase 2, multicenter, multiple-arm, open-label study to evaluate the efficacy, safety, and tolerability of EZN-2208. EZN-2208 will be administered as a single agent in patients with K-RAS mutations in the tumors. Patients with wild type K-RAS in tumors will be randomized to EZN-2208 + cetuximab or to standard of care (Camptosar® + cetuximab), patients must have failed regimens containing irinotecan (Camptosar®, CPT-11), oxaliplatin (Eloxatin®), and fluoropyrimidine.

After discontinuation of study treatment, patients will receive care as considered appropriate by the investigator. Patients will continue to be followed for disease progression, subsequent anticancer therapy, and survival.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days. PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.
ezn-2208, cetuximab and irinotecan Irinotecan, (CPT 11),(Camptosar®)
Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL. Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C).
(Experimental)
Cetuximab will be administered as an i.v. infusion on weekly basis. EZN-2208 administered as i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
ezn-2208, cetuximab and irinotecan Irinotecan, (CPT 11),(Camptosar®)
Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL. Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C).
(Active Comparator)
Cetuximab will be administered weekly as an i.v. infusion. Irinotecan will be administered as an i.v. infusion on Weeks 1 and 2 and repeated every 3 weeks.
ezn-2208, cetuximab and irinotecan Irinotecan, (CPT 11),(Camptosar®)
Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL. Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C).

Primary Outcomes

Measure
Response Rate
time frame: 2011

Secondary Outcomes

Measure
Progression Free Survival (PFS)
time frame: 2011

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients must meet all of the following criteria to be eligible for enrollment in the study. 1. Histologically confirmed CRC adenocarcinoma that is metastatic or locally recurrent CRC that is nonresectable 2. Patients must agree to genetic testing of the original or metastatic CRC tumor biopsy tissue for K-RAS mutational status. 3. Disease progression 4. Previous therapy with irinotecan, oxaliplatin, and fluoropyrimidine either alone or in any combination(s). Patients must have radiographically documented progressive disease while receiving, or within 3 months of receiving, these agents alone or in combination. 5. No more than 2 prior cytotoxic chemotherapy regimens. 6. Age 18 years or older 7. Measurable disease by RECIST Version 1.1 8. ECOG performance status of 0 or 1 9. Adequate bone marrow, renal, and hepatic function Exclusion Criteria: - Patients meeting any of the following exclusion criteria will not be eligible for enrollment. 1. Known chronic infectious disease 2. Major surgery within 3 weeks before study start 3. Known or suspected brain metastases requiring intervention with steroids and/or radiation therapy. 4. Prior chemotherapy, immunotherapy, non-investigational agent, or other therapy used to treat the cancer within 3 weeks before the scheduled administration of EZN-2208 5. History of other primary cancer within 5 years of enrollment, unless 1. Curatively resected non-melanomatous skin cancer, or 2. Curatively resected cervical cancer 6. Lack of recovery to Grade 1 from any reversible side effects related to the administration of an investigational agent, or other prior treatments for the cancer 7. Any condition such as uncontrollable diabetes, uncontrollable hypertension, or active infection. 8. Current participation in another clinical study with an investigational agent and/or use of an investigational drug (not including investigational use of an approved drug) in the 30 days before the first administration of EZN-2208

Additional Information

Official title A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Principal investigator Richard M. Goldberg, MD
Description EZN-2208 will be administered by i.v. infusion weekly for 3 weeks in 4-week cycles. The cetuximab infusion will be administered before the EZN-2208 (Arm B) or irinotecan (Arm C) infusion. Study treatment will be continued until evidence of disease progression, unacceptable toxicity, or withdrawal of the patient's consent for participation in the study. Approximately 220 patients will be enrolled in this study: approximately 100 patients in the K-RAS mutated arm and approximately 120 patients in the wild-type K-RAS arm.
Trial information was received from ClinicalTrials.gov and was last updated in September 2011.
Information provided to ClinicalTrials.gov by Enzon Pharmaceuticals, Inc..